One study, lasted a month, reported that GHK-Cu might stimulate type 1 collagen production in clinical settings
Considerations include: Lower initial dosing where appropriate Close monitoring for gastrointestinal intolerance Assessment of comorbidities and polypharmacy risks 15.2 Administration to Pregnant Women Human data remain limited
Cascinu S, Cordella L, ferro E et al
Prior coverage of Luvo Health's broader program lineup, brand-wide reviews, and complaint research goes deeper on that company-wide picture
Again, coverage is only likely when the GLP-1 drug is prescribed for an FDA-approved use
doi: 10.3389/fendo.2025.1483199 Received 19 August 2024 Accepted 10 January 2025 Published 17 February 2025 Volume 16 - 2025 Edited by Brenda Kohn, New York University, United States Reviewed by Ekaterina Koledova, Merck, Germany Torben Laursen, Aarhus University Hospital, Denmark Updates Copyright 2025 Levshtein, Sharkia, Shimshi-Barash, Almagor, Albertsson-Wikland, Hochberg, Pillar and German